首页> 外文期刊>BMC Ophthalmology >Belatacept associated - cytomegalovirus retinitis in a kidney transplant recipient: a case report and review of the literature
【24h】

Belatacept associated - cytomegalovirus retinitis in a kidney transplant recipient: a case report and review of the literature

机译:BelataCept相关 - 肾移植受体中的巨细胞病毒视网膜病毒:一个案例报告和对文献的审查

获取原文
           

摘要

To report the first case of belatacept-associated multidrug-resistant Cytomegalovirus retinitis in a kidney transplant recipient. A 76-year-old African male renal allograft recipient was admitted for acute visual loss of the right eye. Ophthalmological examination of the right eye showed anterior uveitis and vitritis associated with large paravascular haemorrhages and yellow necrotic borders, involving the posterior pole but not the fovea. Both Cytomegalovirus DNA in plasma and aqueous humor were positive. The patient had had several episodes of Cytomegalovirus reactivation subsequent to the introduction of belatacept. His cytomegalovirus was multi-drug resistant, and was treated with maribarir, intravitreal and systemic injections of foscarnet, and anti-Cytomegalovirus human immunoglobulin. In parallel, belatacept was stopped and switched to tacrolimus. Cytomegalovirus DNA became undetectable and there was partial improvement of visual acuity at the last ophthalmologic examination, 18?months after the initial diagnosis of Cytomegalovirus retinitis. Cytomegalovirus retinitis is an uncommon opportunistic infection in kidney transplant recipients. Cytomegalovirus retinitis is a serious infection because of the risk of blindness and the occurrence of associated life-threatening opportunistic infections. In view of the recent literature, kidney transplant recipients treated by belatacept immunosuppression may be at increased risk for Cytomegalovirus disease, notably Cytomegalovirus retinitis. The occurrence of Cytomegalovirus retinitis may help improve the selection of patients converted to belatacept.
机译:在肾移植受体中报告第一种BelataCept相关的多药物抑制细胞病毒视网膜炎。一个76岁的非洲男性肾同种异体移植受体被禁止急性视力丧失。右眼的眼科检查显示出与大型旁向血管出血和黄色坏死的边界相关的前葡萄膜炎和血栓炎,涉及后杆,但不是FOVEA。血浆中的塞细胞病毒DNA均为阳性。在引入BelataCept之后,患者患有几次细胞核病毒再活化。他的细胞病毒是多种毒性的,并用野生动物,玻璃体玻璃体和嗜肺病毒注射治疗,以及抗缩细胞病毒人免疫球蛋白。平行,白皮根停止并切换到躯干司。 Cytomegalovirus DNA变得无法察觉,并且在最后一次眼科检查时,视力的部分改善,18次缩短诊断细胞病毒视网膜炎炎症症后的敏捷。鼻腔病毒视网膜病毒是肾移植受者的罕见机会感染。由于失明的风险和相关的危及生命的机会主义感染的风险,巨细胞病毒视网膜炎是严重的感染。鉴于最近的文献,BelataCept免疫抑制治疗的肾移植受者可能是巨细胞病毒疾病的风险增加,特别是缩细胞病毒视网膜炎。患细胞瘤病毒视网膜炎的发生可能有助于改善转化为BelataCept的患者的选择。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号